Abstract mRNA technologies have recently proven clinical efficacy against coronavirus
disease 2019 and are among the most promising technologies to address the current …

RNA vaccines have demonstrated efficacy against SARS-CoV-2 in humans, and the
technology is being leveraged for rapid emergency response. In this report, we assessed …

Immune correlates of protection can be used as surrogate endpoints for vaccine efficacy.
The nonhuman primate (NHP) model of SARS-CoV-2 infection replicates key features of …

The continued evolution of SARS-CoV-2 has raised questions regarding the ability of prior
immunity to early pandemic strains to afford protection against emerging variants. In a recent …

Carrier-free naked mRNA vaccines may reduce the reactogenicity associated with delivery
carriers; however, their effectiveness against infectious diseases has been suboptimal. To …

The inclusion of infants in the SARS-CoV-2 vaccine rollout is important to prevent severe
complications of pediatric SARS-CoV-2 infections and to limit transmission and could …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of
the COVID-19 global pandemic. SARS-CoV-2 is an enveloped RNA virus that relies on its …

There is an urgent need for a broad-spectrum and protective vaccine due to the emergence
and rapid spreading of more contagious SARS-CoV-2 strains. We report the development of …

The CVnCoV (CureVac) mRNA vaccine for SARS-CoV-2 has recently been evaluated in a
phase 2b/3 efficacy trial in humans. CV2CoV is a second-generation mRNA vaccine with …

In pandemic scenarios involving novel human pathogenic viruses, it is highly desirable that
vaccines induce strong neutralizing antibodies as quickly as possible. However, current …